12:00 AM
Apr 27, 2009
 |  BC Week In Review  |  Company News  |  Deals

Vectura, Novartis deal

Vectura received a €2.5 million ($3.3 million) milestone payment from Novartis under a 2006 deal granting Novartis' Sandoz International GmbH generics unit European rights to develop and commercialize Vectura's

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >